United States securities and exchange commission logo





                               January 22, 2024

       Kevin Tang
       Chief Executive Officer
       Concentra Biosciences, LLC
       4747 Executive Drive, Suite 210
       San Diego, CA 92121

                                                        Re: Concentra
Biosciences, LLC
                                                            Theseus
Pharmaceuticals, Inc.
                                                            Schedule TO-T Filed
January 9, 2024
                                                            Filed by Concentra
Merger Sub II, Inc., Concentra Biosciences, LLC, Tang
                                                            Capital Partners,
LP, and Tang Capital Management, LLC
                                                            File No. 005-92944

       Dear Kevin Tang:

                                                        We have reviewed your
filing and have the following comments.

               Please respond to these comments by providing the requested
information or advise us as
       soon as possible when you will respond. If you do not believe our
comments apply to your facts
       and circumstances, please tell us why in your response.

               After reviewing your response to these comments, we may have
additional comments.
       All defined terms used herein have the same meaning as in your offer
materials, unless otherwise
       indicated.

       Schedule TO-T Filed January 9, 2024

       General

   1.                                                   Refer to the disclosure
in the introductory section of the Offer to Purchase regarding the
                                                        determination of the
Additional Price Per Share. The disclosure states that "the Offer will
                                                        remain open for at
least ten (10) business days from the date the supplement or
                                                        amendment to this Offer
to Purchase that includes the finally determined Additional Price
                                                        Per Share is filed with
the SEC." Rule 14e-1(b) requires that when a change in the offer
                                                        consideration occurs,
an offer must remain open for at least ten business days from the
                                                        date "that notice of
such increase or decrease is first published or sent or given to security
                                                        holders." Please revise
your disclosure accordingly, and to describe how you will
                                                        disseminate notice of
the price change in addition to filing an amendment on EDGAR.
 Kevin Tang
FirstName  LastNameKevin
Concentra Biosciences, LLCTang
Comapany
January 22,NameConcentra
            2024          Biosciences, LLC
January
Page 2 22, 2024 Page 2
FirstName LastName
2.       We note the disclosure on page 4 of the Offer to Purchase that "the
co-offerors estimate
         that the amount that will be payable under the CVRs is most likely
$0.00 per CVR . . . ."
         Revise the Offer to Purchase generally to explain the basis for the
co-offerors' belief with
         respect to the CVRs.
3.       Expand generally throughout the offer materials to discuss the
specific risks and
         uncertainties concerning the events that must occur (or not occur) in
order for payment to
         be issued under the terms of the CVRs, including specific disclosure
about the current
         status of the development of the CVR Products.
4.       Your disclosure regarding the calculation of the Additional Price Per
Share is unclear as to
         the fact that it is capped at $0.15 per Share and on the basis for
such cap. In this regard,
         we note that the definition of Closing Net Cash in the Merger
Agreement does not appear
         to include a cap. The Merger Agreement references a Schedule I for the
manner in which
         the Closing Net Cash is calculated, but that schedule is omitted from
Exhibit (d)(1). Please
         revise the disclosure generally where the formula for calculating the
Additional Price Per
         Share is set forth, to clearly state that regardless of the value
yielded, the Additional Price
         Per Share will be capped at $0.15. In addition, explain the basis for
this cap.
5.       It appears that you have filed an Amended and Restated Investors'
Rights Agreement in
         response to Item 1011(a)(1) of Regulation M-A. That Item requires
disclosure of any
         material agreement between an offeror and the subject company or their
respective control
         persons. However, the Offer to Purchase does not describe the
Investors' Rights
         Agreement, so it is not clear how this agreement is responsive to Item
1011(a)(1). Please
         revise or advise.
6.       In future filings, please avoid the excessive use of defined terms,
which impacts
         shareholders' ability to understand the terms of the Offer.
Background of the Offer; Contacts with Theseus, page 16

7.       We note on page 17 of the Offer to Purchase that Parent, Purchaser,
and Theseus, along
         with their respective representatives, exchanged drafts of the CVR
Agreement, Limited
         Guaranty and Merger Agreement from December 20, 2023 to December 21,
2023. Please
         revise your disclosure in this section to provide more detail
regarding any
         communications or negotiations concerning TCP providing the Limited
Guaranty.
Summary of the Merger Agreement and Certain Other Agreements, page 34

8.       On pages 45-46 of the Offer to Purchase, you summarize the CVR
Agreement. Please
         revise this disclosure to clarify the period for which CVR holders are
entitled to
         Disposition Proceeds if a Disposition occurs during the Disposition
Period. See the
         definition of    Expiration Date    in the CVR Agreement.
9.       See above comment. Please also revise the summary of the CVR Agreement
to indicate
         that the CVR Agreement may be amended without the consent of the CVR
holders in
         certain circumstances. See Section 5.1 of the CVR Agreement.
 Kevin Tang
FirstName  LastNameKevin
Concentra Biosciences, LLCTang
Comapany
January 22,NameConcentra
            2024          Biosciences, LLC
January
Page 3 22, 2024 Page 3
FirstName LastName
10.      Refer to the following statement made on page 46 of the Offer to
Purchase:    Parent   s and
         TCP   s obligations under the Confidentiality Agreement will expire
one year after the date
         of the Confidentiality Agreement.    Please revise this disclosure to
clarify that the non-
         solicitation provision of the Confidentiality Agreement survives the
termination of the
         agreement. See Section 6 and 20 of the Confidentiality Agreement.
Source and Amount of Funds, page 46

11.      Refer to the following statement made on page 46 of the Offer to
Purchase:    The funds to
         pay for all Shares accepted for payment in the Offer may be funded
entirely with Theseus
         available cash    (emphasis added). Please revise to state the other
source(s) of payment if
         all or a portion of the Cash Amount is not funded from Theseus
available cash. See Item
         7 of Schedule TO and Item 1007(a) of Regulation M-A.
12.      On page 47 of the Offer to Purchase you state that you "do not believe
our financial
         condition is relevant to your decision whether to tender your Shares
and accept the
         Offer." However, on page 4 of the Offer to Purchase you state that
"Parent's and
         Guarantor's financial condition could deteriorate such that they would
not have the
         necessary cash or cash equivalents to make the required payments
pursuant to the CVR
         Agreement." In addition, we note that this is not an all-cash offer
and therefore does not fit
         the fact pattern described in Instruction 2 to Item 10 of Schedule TO.
Although you note
         on page 8 of the Offer to Purchase that Purchaser was "organized
solely in connection
         with the Merger Agreement and this Offer" and "does not have any
relevant historical
         information," as you are aware, there are other offerors on the
Schedule TO. Please revise
         or advise.
Conditions of the Offer, page 47

13.      Refer to the following statement made in the first paragraph after the
bullet points on page
         48 of the Offer to Purchase: "The foregoing conditions shall be in
addition to, and not a
         limitation of, the rights of Parent and Purchaser to extend, terminate
or modify the Offer
         in accordance with the terms and conditions of the Merger Agreement."
Please revise this
         section to describe all Offer conditions.
 Kevin Tang
Concentra Biosciences, LLC
January 22, 2024
Page 4

        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

      Please direct any questions to Shane Callaghan at 202-551-6977 or
Christina Chalk at
202-551-3263.



FirstName LastNameKevin Tang                                Sincerely,
Comapany NameConcentra Biosciences, LLC
                                                            Division of
Corporation Finance
January 22, 2024 Page 4                                     Office of Mergers &
Acquisitions
FirstName LastName